Medistem Laboratories (OTCBB: MEDS) today reported positive efficacy data supporting development of its lead product, the Endometrial Regenerative Cell (ERC) for treatment of an advanced form of peripheral artery disease known as critical limb ischemia.

A startup stem cell company with part of its operations in San Diego has discovered a new type of stem cell in menstrual blood, a finding that might allow researchers to avoid the medical and ethical issues surrounding the use of human embryonic stem cells.